Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Apabetalone with Atorvastatin or Rosuvastatin in Dyslipidemia
NCT01863225Phase 2Terminated
- Sponsor
- Resverlogix Corp.
- Start
- May 2013
- Primary completion
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of apabetalone in dyslipidemia (4 arms), sponsored by Resverlogix Corp. Primary endpoint: Characterization of the pharmacokinetics of RVX000222 capsule formulation at 14 days. Started May 2013; status: terminated.
02
Drugs
apabetalone
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT01863225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01863225.